Company intelligence / Profile preview
Iscador AG
- Ownership
- Private
- Employees
- ~100
- Development stage
- Commercial
Overview
Iscador AG manufactures ISCADOR®, a fermented aqueous extract of white mistletoe used as an adjunctive therapy in cancer treatment. The product has been prescribed for nearly a century as part of integrative oncology approaches. Clinical studies suggest benefits in quality of life, immune modulation, and possible survival improvement when used alongside conventional therapies. Ongoing clinical trials include Phase 2 studies in relapsed osteosarcoma patients post-metastasectomy.
- Therapeutic areas
- Oncology
- Modalities
- Plant extracts (specifically fermented mistletoe extract)
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Iscador AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iscador AG.